Specifically, the brightest 7% of AML blasts for E-selectin-binding-potential were >12-fold more likely to survive post-chemotherapy in vivo compared to lowest 50% for E-selectin binding (Fig. 5c). The gene discussed is SELE; the disease is acute myeloid leukemia.